Lipocine Inc. (LPCN) stock
LPCNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 11/3048% below fair value
$1.71+0.09 (+5.56%)
Close on Nov 13, 2026Market cap $14.10MP/E –Yield –
Lipocine enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Lipocine's enterprise value was -$10.16M on Nov 11, 2026, against $3.51M a year earlier. Over the last 5 years it ranged from -$12.44M to $78.66M, with a median of -$550.83K.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | -$10.16M | -135.8% |
| 2025 | Dec 31, 2025 | $28.39M | +352.5% |
| 2024 | Dec 31, 2024 | $6.27M | – |
| 2023 | Dec 29, 2023 | -$9.02M | -1043.3% |
| 2022 | Dec 30, 2022 | $955.87K | -98.2% |
| 2021 | Dec 31, 2021 | $51.98M | -32.4% |
| 2020 | Dec 31, 2020 | $76.90M | +7412.6% |
| 2019 | Dec 31, 2019 | $1.02M | -97.3% |
| 2018 | Dec 31, 2018 | $37.93M | -40.4% |
| 2017 | Dec 29, 2017 | $63.59M | +1.8% |
| 2016 | Dec 30, 2016 | $62.47M | -70.5% |
| 2015 | Dec 31, 2015 | $211.97M | +496.3% |
| 2014 | Dec 31, 2014 | $35.55M | -33.6% |
| 2013 | Dec 31, 2013 | $53.52M | – |
See a number that looks wrong?